Navigation Links
Hospira Reports Third-Quarter 2012 Results
Date:11/7/2012

as indicated in the previous footnote.Hospira, Inc.Reconciliation of GAAP to Non-GAAP Financial Measures(Unaudited)(dollars in millions, except for per share amounts)Three months ended September 30, 2012 Reconciliation of GAAP to Non-GAAP Financial Measures:Gross Profit (1) (Loss) Income

From Operations Net Income (2)Diluted EPSGAAP financial measures$
214.3$
(16.5)$
.2$
.01Specified items:   Amortization of certain intangible assets (A)18.318.312.40.07   Impairment of certain assets (B)-11.38.20.05   Certain quality and product related charges (C)97.397.360.90.37   Capacity expansion related charges (D)4.14.12.40.01   Other restructuring charges (E)-(1.9)(6.7)(0.04)Adjusted financial measures (3)$
334.0$
2.6$
78.4$
.47GAAP results for the three months ended September 30, 2012 include:(A)

Amortization of certain intangible assets reported in Cost of products sold resulting from acquisitions including Mayne Pharma Limited ("Mayne Pharma"), Javelin Pharmaceuticals, Inc. ("Javelin Pharma") and a generic injectable business by Hospira Healthcare India Private Limited ("Hospira India").(B)

Impairment of certain assets: $11.3 million reported in Restructuring, impairment, and (gain) on disposition of assets, net, related to impairments of certain intangible assets.(C)

Certain quality and product related charges reported in Cost of products sold primarily include third party oversight and consulting costs, extended production downtime related costs, device product review and remediation costs to address identified issues, and costs for corrective actions. These charges are directly associated with Hospira's response to the United States Food and Drug Administration (
'/>"/>

SOURCE Hospira, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
2. Hospira Reports First-Quarter 2012 Results
3. Hospira to Present at Upcoming Investor Conferences
4. I.V. Clinical Integration Helps Deliver Safety, Efficiency And Financial Benefits; Hospira Shares Snapshot Of Results, Process
5. Hospira and Lancaster General Hospital Honored for Patient Safety Initiatives
6. Hospira to Host Conference Call for Second-quarter 2012 Results
7. Hospira Expands Board of Directors With Election of Dennis M. Fenton
8. Hospira Reports Second-Quarter 2012 Results
9. Hospira to Acquire Active Pharmaceutical Ingredient Manufacturing and R&D Facilities
10. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
11. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... 19, 2014 Luoxis Diagnostics, Inc. ... (NYSE MKT: AMPE), today announced an upcoming ... of the American Academy of Surgical Trauma (AAST) ... Philadelphia, Pennsylvania that will ... report results from a recently completed five-year prospective ...
(Date:8/18/2014)... Japan , Aug. 19, 2014 Boston ... INTECC (Securities Code 7747, Second Section, Tokyo ... to develop a new, differentiated fractional flow reserve (FFR) ... intended to improve handling compared to existing FFR wires. ... in interventional cardiology that exceeds $250 million worldwide and ...
(Date:8/18/2014)... , Aug. 18, 2014 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p01597713/Bioseparation-Systems-for-Global-Biopharmaceutical-Markets.html ... into three types: chromatography, membranes/filters and centrifuges. ... increasing and fueling growth of the global ...
Breaking Medicine Technology:Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 2Luoxis Announces Presentation of Positive Clinical Findings from Five-Year Clinical Study of Traumatic Brain Injury and Oxidation-Reduction Potential at 2014 American Academy of Surgical Trauma Meeting 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 2Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 3Boston Scientific and ASAHI INTECC Announce Joint Development and Manufacturing Programs 4Bioseparation Systems for Global Biopharmaceutical Markets 2Bioseparation Systems for Global Biopharmaceutical Markets 3Bioseparation Systems for Global Biopharmaceutical Markets 4Bioseparation Systems for Global Biopharmaceutical Markets 5Bioseparation Systems for Global Biopharmaceutical Markets 6Bioseparation Systems for Global Biopharmaceutical Markets 7Bioseparation Systems for Global Biopharmaceutical Markets 8Bioseparation Systems for Global Biopharmaceutical Markets 9Bioseparation Systems for Global Biopharmaceutical Markets 10Bioseparation Systems for Global Biopharmaceutical Markets 11Bioseparation Systems for Global Biopharmaceutical Markets 12
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:8/20/2014)... DC (PRWEB) August 20, 2014 Hope ... Heart, Give Hope® Celebration to be hosted in Washington, ... and Navy Club. This signature event honors the courage ... families of the fallen. Proceeds from the Got Heart, ... a national nonprofit dedicated to restoring a sense of ...
(Date:8/20/2014)... Building on growing success by applying ... iii and iv pressure ulcers with extremely high ... A company spokesperson commented that these accuracy levels ... settings. The resulting capabilities can be extended to ... to help providers avoid financial losses while improving ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Blaine ... the innovative RevitaDERM® Psoriasis Treatment to ... associated with psoriasis. This all-in-one product was created ... RevitaDERM® Psoriasis Treatment is powered by coal tar ... associated with this effective ingredient. , RevitaDERM® ...
(Date:8/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sodium Chloride IV . , ... of Sodium Chloride IV 0.9%, USP 1000 mL, by Baxter ... of particulate matter. Sodium Chloride Injection, USP is used as ... solution in hemodialysis procedures. , The reason for ...
(Date:8/20/2014)... NY (PRWEB) August 20, 2014 At this ... of Africa. To help eliminate the root cause of the ... recently teamed up with the nonprofit organization Books For Africa ... Africans: How Every African Can Live the Life of Their ... , This book equips Africans with the tools they need ...
Breaking Medicine News(10 mins):Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:Jvion Achieves Benchmark Accuracy in Pressure Ulcer Prediction 2Health News:RevitaDERM® Psoriasis Treatment Now Available At Over 7,600 CVS/pharmacies 2Health News:Sodium Chloride IV 0.9% by Baxter Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 2Health News:Ebola, Poverty, and a Partnership for Africa—How Everyone Can Help 3
... broader, patient-centered treatment choices to those ... dealing with substance use disorders, WASHINGTON, ... awarded a $7 million contract to provide technical,assistance to the ... Mental Health Services Administration (SAMHSA) within,the U.S. Department of Health ...
... Serious subject for the funnies becomes basis for Lisa,s Legacy ... in a comic strip,Funky Winkerbean creator Tom Batiuk has depicted ... of breast cancer. Lisa Moore, a major,character who is battling ... Oct. 4, 2007, leaving behind her husband, Les, and their,five-year-old ...
... 2, 2007 Phylonix Pharmaceuticals, Inc. today announced that it ... Grant (SBIR) from the National Eye Institute of the National ... for drug screening. The grant for New Models for ... of three years., The eye is a highly conserved organ ...
... Paramed Systems announced today,the release of their Mobility Offers ... fire, emergency medical, and,rehabilitating patients safely and easily both ... a button. Paramed developed the dual-track MOV in ... capable of safe stairway ascents and,descents. The MOV has ...
... a Full-featured Solution for Home ... DALLAS, Oct. 2 Today, Dynamic Energy Systems, Inc.,(DES) ... on- demand, on-line software solution. The online version,provides access ... so excited to offer our customers a choice when ...
... the Modernization, of its Health Information System Based on BEA ... ... (Assistance Publique - Hopitaux de Marseille) has chosen BEA ... Integration offers an interoperability platform upon which AP-HM has built ...
Cached Medicine News:Health News:Altarum Wins $7 Million Contract to Provide Technical Assistance to the Access to Recovery Program 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 2Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 3Health News:University Hospitals Ireland Cancer Center and Funky Winkerbean Cartoonist Tom Batiuk Establish Lisa's Legacy Fund for Cancer Research and Education 4Health News:NIH awards Phylonix phase II SBIR to develop zebrafish models for eye diseases 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 2Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 3Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 4Health News:AP-HM Places Patients at the Core of its Service-Oriented Architecture with BEA Systems 5
Femoral selective diagnostic catheter.The material used is polyurethane (DUCOR). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
Jography angiographic catheter has a new material combination, a patented angled weld, a flat wire braid design with a XXL lumen. It also has an atraumatic soft tip....
Femoral selective diagnostic catheter. The material used is nylon (VESTANTM). All selective shapes have thrulumen design. Guidewire campatibility is 0.038". Packaging 5/Box....
... of cardiology catheters. Available in both Softouch ... with excellent torque, new wire-braid technology for ... large inner lumens for excellent flow rates. ... French sizes with pressure ratings up to ...
Medicine Products: